This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

ZAVICEFTA® (ceftazidime-avibactam): For the treatment of adult and paediatric patients aged 3 months and older at high risk of MDR Gram-negative infections1

ZAVICEFTA is indicated for the treatment of adult and paediatric patients aged 3 months and older with the following infections:1

- Complicated urinary tract infection (cUTI),  including pyelonephritis
- Complicated intra-abdominal infection (cIAI)
- Hospital-acquired pneumonia, including ventilator-associated pneumonia (HAP/VAP)
- Infections due to aerobic Gram-negative organisms in patients with limited treatment options†

ZAVICEFTA demonstrated similar effectiveness to comparator therapies (meropenem or cefepime) when assessed in paediatric trials*2,3

ZAVICEFTA has a similar safety and tolerability profile in paediatric patients aged 3 months and older with cIAI and cUTI to that observed in adults*1-3

The safety assessment in paediatric patients is based on data from two trials in which 61 patients with cIAI and 67 patients with cUTI aged 3 months to < 18 years received ZAVICEFTA1

Card Header

Most common adverse reactions (>3%) for ZAVICEFTA were vomiting, diarrhoea, rash, and infusion site phlebitis2,3

Card CTA

** This is an optional area where footnotes can live.

Card Header

Low rates of discontinuation due to adverse effects and no deaths were reported in either study2,3

Card CTA

** This is an optional area where footnotes can live.

† Data support the use of ZAVICEFTA in adult patients with Limited Treatment Options for the treatment of bacteraemia (both primary and secondary), cSSTI, BJI, meningitis due to KPC and OXA-48 resistance mechanisms, and MDR Pseudomonas.4–10

* ZAVICEFTA has been evaluated in paediatric patients aged 3 months to < 18 years in two Phase II single-blind, randomised, comparative clinical studies, one in patients with cIAI and one in patients with cUTI (N=128). In the cIAI trial, patients received ZAVICEFTA plus metronidazole, and in the cUTI trial, patients received ZAVICEFTA alone. The primary objective in each study was to assess safety and tolerability of ZAVICEFTA (+/- metronidazole). Secondary objectives included assessment of pharmacokinetics and efficacy; efficacy was a descriptive endpoint in both studies.1,2,3​​​​​​​
​​​​​​​

Explore more

Pathogen coverage

ZAVICEFTA has broad spectrum coverage against Gram-negative pathogens including in vitro activity against MDR P.aeruginosa, CRE, including KPC- and OXA-48 producing strains, and ESBL- and AmpC-producing bacteria1-4.

Read more

Patient Risk factors

Identifying patients at risk of MDR Gram-negative infections is vital for appropriate selection of adequate, early antimicrobial therapy to reduce the risk of fatal outcomes5.

Read more

Abbreviations:

cUTI, complicated urinary tract infection, cIAI, complicated intra-abdominal infection; HAP, hospital-acquired pneumonia; VAP, ventilator-associated pneumonia; MDR, multi-drug resistant; KPC, Klebsiella pneumoniae carbapenemase; OXA, oxacillinase; BJI, bone and joint infection;

​​​​​​​Prescribing information

Zavicefta (ceftazidime and avibactam) 2g/0.5 g Powder for Concentrate for Solution for Infusion

Meronem® (meropenem triydrate) IV 1g 
​​​​​​​
​​​Meronem® (meropenem triydrate) IV 500mg 

​​​​​​​References

  1. ZAVICEFTA. Summary of Product Characteristics, 2021; 
  2. Bradley JS, et al. Pediatr Infect Dis J 2019;38:816–24;
  3. Bradley JS, et al. Pediatr Infect Dis J 2019;38:920–8.
  4. Tumbarello M, et al. Clin Infect Dis 2012;55:943–50; 
  5. Caston JJ, et al. J Infect Dis 2017;59:118–23; 
  6. van Duin D, et al. J Clin Infect Dis 2016;66:163–71; 
  7. Sousa A, et al. Antimicrob Chemother 2018;73:3170–5; 
  8. Temkin E, et al. Antimicrob Agents Chemother 2017;61:e01964-16; 
  9. Shields K, et al. Antimicrob Agents Chemother 2017;61:e00883-17; 
  10. Tumbarello M, et al. Clin Infect Dis 2019;68:355–64;

    ​
PP-ZVA-GBR-1206. June 2021

Learn more about ZAVICEFTA’s Phase III clinical trials in adult patients with cUTI, cIAI and HAP/VAP.

Learn more about efficacy

Access results of ZAVICEFTA Phase III clinical trials in adult patients with cUTI, CIAI, or HAP/VAP

  • REPROVE Phase III trial (HAP/VAP)
  • RECLAIM Phase III trial (cIAI)
  • RECAPTURE Phase III trial (cUTI)
  • REPRISE Phase III trial (cIAI and cUTI)
View Support & Services

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No